Washington, D.C.—The Natural Products Association (NPA) has announced that Douglas Kalman, Ph.D., R.D., will be the association’s new Director of Scientific Affairs.

“Science is at the core of everything we do at NPA, and having an accomplished scientific advisor like Dr. Douglas Kalman on board will help us in our mission to aggressively promote and defend the natural products industry,” said Daniel Fabricant, President and CEO of NPA, in the press release. “His expertise in nutrition, clinical trials, and dietary ingredients will be extremely helpful to our efforts to educate regulators and elected officials alike on the importance of these products and why Americans find them so beneficial.”

Kalman was most recently the Vice President of Scientific Affairs for Nutrasource, and is currently on Faculty in the Dr. Kiran C. Patel College of Osteopathic Medicine at Nova Southeastern University in Florida. He has also previously served the American Society for Nutrition, American College of Sports Medicine, International Society of Sports Nutrition, National Strength & Conditioning Organization, American Physiological Society, the Academy of Nutrition and Dietetics, the United States Tennis Association, United States Track and Field, and more.

Related: NPA Files Citizen’s Petition on Legality of CBD Associations Submit Comments on FDA’s Tentative Response to NAC Petitions People News: March 2022

“On behalf of the Nutrasource Team, we wish to thank Dr. Kalman for his many contributions to the growth of the company during his tenure,” said William J. Rowe, President and CEO of Nutrasource. “Although it is always tough to say good-bye to a key colleague, we wish Dr. Kalman much success in his new role with NPA and are excited for him as he embraces new opportunities for growth in the areas of education, policy and advocacy for the Natural Products Industry.”

Dr. Kalman commented: “I am very pleased to be joining NPA, which is the most influential and leading trade association in our industry. NPA is at the forefront of every leading public policy debate in terms of the legal and regulatory challenges facing the industry, and I look forward to working with them to pursue our advocacy objectives.”